You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202341 - 202350 of 207712 results
  1. Selective activation of the vagus nerve as an improved therapy for heart failure

    SBC: BLACKROCK MICROSYSTEMS, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): The goal of the proposed project is to alleviate the enormous public health burden of heart failure. Heart failure leads to significant morbidity and mortality, affects almost five million Americans, and results in morethan 35 billion dollars in annual healthcare costs. Current pharmacological and surgical treatments are only moderately effective and can have s ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a Nrf2 activator for the treatment of COPD

    SBC: CUREVEDA, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity worldwide. In the US alone, the disease afflicts ~13 million people and is the third-leading cause of death. Cigarette smoking isthe primary risk factor for COPD, initiating a persistent and progressive inflammatory immune response. Respiratory infections and pollutants can ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NHLBI

    We have discovered the first-ever inhibitors of PF4, a platelet protein central to the pathophysiology of heparin induced thrombocytopenia (HIT). Heparin is a naturally-occurring anticoagulant that prevents the formation of clots and extension of existingclots within the vasculature, and major medical applications of heparin include dialysis, cardiac catheterization, and cardiopulmonary bypass sur ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Novel coatings releasing synergistic polyphenols promote vascular healing

    SBC: REQUISITE BIOMEDICAL, LLC            Topic: NHLBI

    PROJECT SUMMARY Cardiovascular disease (CVD) remains the number one cause of death in the U.S. Left untreated, CVD can result in the occlusion of key arteries that can precipitate a major cardiac event. Clinicians routinely correct arterial blockages mechanically using a balloon expansion of the lesioned area and placement of a metallic stent to help keep the arteries open. However, the overstretc ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. POC 2-D Diffusion Assay for self-monitoring of BNP

    SBC: SENTILUS            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of this STTR proposal is to develop a 2-D diffusion point-of-care assay (POC) for B-type natriuretic peptide (BNP). The primary goal of the proposed work is to create a test format that will allow patientswith chronic heart failure to quantitatively self-monitor serum levels of BNP. Determination of baseline level of BNP and changes in this level ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. High Intensity Ultrasonic Device for Mitigating Neonatal Perioperative Bleeding

    SBC: BIODESIGN RESEARCH AND DEVELOPMENT, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congenital heart disease (CHD) ranges from benign lesions to life-threatening structural abnormalities. While benign lesions may resolve without intervention, severe structural lesions require complex pediatric cardiacsurgery. The reconstruction of the aortic arch in children is a complex repair in which perioperative bleeding i a significant, important and fre ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Sympathetic Nerve Activity Recorded From the Skin and Cardiac Arrhythmias

    SBC: ARRHYTHMOTECH            Topic: NHLBI

    DESCRIPTION (provided by applicant): The broad and long-term objective of this research project is to use, develop and market an instrument for the simultaneous recording of sympathetic nerve activity (SNA) and electrocardiogram (ECG) using electrodes on the skin. This method (neuECG) was discovered in Dr. Chen's research laboratory at the Krannert Institute of Cardiology, and a patent applic ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. A novel therapeutic approach for Acute Lung Injury/ARDS

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: NHLBI

    DESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel pharmacogenomic approach for identifying T cell epitopes in replacement FVI

    SBC: Haplomics            Topic: NIMHD

    DESCRIPTION (provided by applicant): About 30% of congenital Hemophilia A (HA) patients develop alloantibodies that neutralize the activity of replacement Factor (F) VIII proteins. Among African American HA patients, the frequency of inhibitor formation ismuch higher; about 50%. Inhibitor patients are typically treated with bypassing agents. Bypassing agents are more expensive and less effective t ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIMHD

    DESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care delivery. While the role of ongoing inflammation during vasooclusive crisis and pain is recognized, effective therapeutic interventions are lacking. Glucocorticoids, with their anti-inflammatory propertie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government